- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03732508
SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer
November 5, 2018 updated by: Jiangsu HengRui Medicine Co., Ltd.
SHR-1316, a Novel Anti-PD-L1 Antibody, in Combination With Irinotecan Liposome and Fluorouracil in Patients With Esophageal Squamous Cell Cancer: a Phase II Study
The purpose of this study is to evaluate the progression-free survival (PFS) of Chemotherapy combined with SHR-1316 in patients with advanced esophageal squamous cell cancer.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fei Shi
- Phone Number: +86-18036618733
- Email: hrshifei@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Recruiting
- Cancer Institute and Hospital,Chinese Academy of Medical Science
-
Contact:
- Jing Huang
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or cytologically confirmed unresectable local advanced/recurrent or metastasis esophageal squamous cell carcinoma;
- No previous systemic anti-tumor treatment;
- Subjects must have at least one measurable tumor lesion per RECIST 1.1;
- ECOG: 0-1;
- Adequate organ and bone marrow function;
Exclusion Criteria:
- Allergic to monoclonal antibodies, any SHR-1316 components,Irinotecan , Fluorouracil ;
Prior therapy as follow:
- Anti-PD-1 or anti-PD-L1;
- Any experimental drugs within 4 weeks of the first dose of study medication;
- Received major operations or serious injuries within 4 weeks of the first dose of study medication;
- Received last dose of anticancer therapy (including chemotherapy, radiotherapy, targeted therapy, etc.) within 4 weeks of the first dose of study medication;
- Not recovered to ≤CTCAE 1 from adverse events (except for hair loss) due to a previously anti-tumor treatment;
- Subjects with any active autoimmune disease or history of autoimmune disease;
- Pregnancy or breast feeding;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Irinotecan liposome plus SHR1316 plus fluorouracil
|
Irinotecan liposome intravenous infusion will be administered during the first day of treatment.
SHR-1316 intravenous infusion will be administered during the first day of treatment.
Fluorouracil intravenous infusion will be administered during the first day of treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Progression-Free Survival (PFS)
Time Frame: approximately 22 months
|
based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)
|
approximately 22 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate(DCR)
Time Frame: approximately 22 months
|
based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)
|
approximately 22 months
|
Objective Response Rate(ORR)
Time Frame: approximately 22 months
|
based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)
|
approximately 22 months
|
Overall Survival(OS)
Time Frame: approximately 22 months
|
OS is defined as the time from registration to death due to any cause, or censored at date last known alive.
|
approximately 22 months
|
Adverse Events(AE)
Time Frame: approximately 22 months
|
adverse events
|
approximately 22 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jing Huang, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2018
Primary Completion (Anticipated)
November 1, 2019
Study Completion (Anticipated)
October 1, 2020
Study Registration Dates
First Submitted
October 31, 2018
First Submitted That Met QC Criteria
November 5, 2018
First Posted (Actual)
November 6, 2018
Study Record Updates
Last Update Posted (Actual)
November 6, 2018
Last Update Submitted That Met QC Criteria
November 5, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Esophageal Neoplasms
- Carcinoma, Squamous Cell
- Esophageal Squamous Cell Carcinoma
- Neoplasms, Squamous Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Fluorouracil
- Irinotecan
Other Study ID Numbers
- IRI-SHR-1316-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Esophageal Squamous Cell Cancer
-
RenJi HospitalRecruitingAdvanced Esophageal Squamous Cell CancerChina
-
Peking UniversityUnknownAdvanced Esophageal Squamous CarcinomaChina
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingAdvanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic ChemotherapyChina
-
Peking Union Medical College HospitalNot yet recruitingAnlotinib | Advanced Esophageal Squamous Cell Cancer | SHR-1210
-
Shandong Cancer Hospital and InstituteRecruitingAdvanced Esophageal Squamous Cell CancerChina
-
Shanghai Chest HospitalRecruitingEsophageal Squamous Cell Carcinoma | Unresectable Locally Advanced Esophageal CancerChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.RecruitingAdvanced Gastric Adenocarcinoma and Esophageal Squamous Cell CarcinomaChina
-
Taiho Oncology, Inc.RecruitingPancreatic Cancer | Esophageal Adenocarcinoma | Esophageal Squamous Cell Cancer | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer | Siewert Type 1 GEJ CancerUnited States, Spain, Germany, France
-
National Cancer Institute (NCI)TerminatedEsophageal Cancer | Esophageal Neoplasms | Esophageal Adenocarcinoma | Squamous Cell Carcinoma | Esophageal Squamous Cell CancerUnited States
-
Cancer Institute and Hospital, Chinese Academy...Akeso Pharmaceuticals, Inc.Not yet recruitingMetastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
Clinical Trials on Irinotecan liposome
-
Fudan UniversityNot yet recruitingSmall Cell Lung Cancer RecurrentChina
-
Baohui HanNot yet recruitingExtensive-stage Small-cell Lung CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Luye Pharma Group Ltd.CompletedAdvanced Solid TumorChina
-
CSPC Ouyi Pharmaceutical Co., Ltd.Not yet recruitingAdvanced Breast Cancer
-
CSPC Ouyi Pharmaceutical Co., Ltd.Not yet recruitingSmall Cell Lung Cancer (SCLC)
-
University of Southern CaliforniaNational Cancer Institute (NCI); IpsenWithdrawnGastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Locally Advanced Unresectable Gastric Adenocarcinoma | Metastatic Unresectable Gastric AdenocarcinomaUnited States
-
PharmaEngineCompletedPancreatic NeoplasmsTaiwan, United States
-
Luye Pharma Group Ltd.Active, not recruitingSmall Cell Lung CancerChina
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology Consortium; The V Foundation for Cancer ResearchCompletedDiffuse Intrinsic Pontine GliomaUnited States